Dr. Mudit Jain, M.D.
Internal Medicine (Internal Medicine Physician)
- Medicare participating
At a glance
- Years since graduation
- 35
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 437
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Internal Medicine Physician primary
FL license ME75960 -
Endocrinology, Diabetes & Metabolism Physician
FL license ME75960
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Holy Cross Hospital Ft Lauderdale, FL
- Westside Regional Medical Center Plantation, FL
Medical groups
- Mudit Jain MD PA (2 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 437
- Services billed
- 1,617
- Patients’ average age
- 74
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 747 | 336 |
| Continuous monitoring of blood sugar level in tissue fluid using sensor under skin with interpretation and report | 113 | 51 |
| Established patient office or other outpatient visit, 40-54 minutes | 108 | 70 |
| New patient office or other outpatient visit, 45-59 minutes | 97 | 97 |
| Ultrasound scan of head and neck soft tissue | 79 | 76 |
| Established patient office or other outpatient visit, 20-29 minutes | 75 | 65 |
| Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | 68 | 68 |
| Annual depression screening, 5 to 15 minutes | 56 | 56 |
| Fine needle aspiration biopsy using ultrasound guidance, first growth | 25 | 24 |
| Fine needle aspiration biopsy using ultrasound guidance, each additional growth | 15 | 13 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Levothyroxine Sodium Other prescribers in Plantation, FL | 804 |
| Ozempic (semaglutide) Other prescribers in Plantation, FL | 701 |
| Metformin Hcl Other prescribers in Plantation, FL | 693 |
| Atorvastatin Calcium Other prescribers in Plantation, FL | 586 |
| Lantus Solostar (insulin glargine,hum.rec.anlog) Other prescribers in Plantation, FL | 478 |
| Jardiance (empagliflozin) Other prescribers in Plantation, FL | 383 |
| Nano 2nd Gen Pen Needle (pen needle, diabetic) Other prescribers in Plantation, FL | 367 |
| Rosuvastatin Calcium Other prescribers in Plantation, FL | 365 |
| Synthroid (levothyroxine sodium) Other prescribers in Plantation, FL | 291 |
| Farxiga (dapagliflozin propanediol) Other prescribers in Plantation, FL | 267 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 20 companies reported 59 payments worth $12,581 in total to this clinician.
| Corcept Therapeutics | $11,002 |
|---|---|
| Medtronic, Inc. | $550 |
| Novo Nordisk Inc | $278 |
| Amgen Inc. | $93.52 |
| Dexcom, Inc. | $89.82 |
| Alexion Pharmaceuticals, Inc. | $84.22 |
| Novartis Pharmaceuticals Corporation | $68.67 |
| Ascendis Pharma Endocrinology Inc | $60.82 |
| Honoraria | $5,545 |
|---|---|
| Compensation for services other than consulting (speaking, faculty) | $3,850 |
| Food and Beverage | $1,732 |
| Travel and Lodging | $1,390 |
| Education | $64.54 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Corcept Therapeutics Sep 17, 2025 | Honoraria Korlym · Endocrinology | $3,725 |
| Corcept Therapeutics May 7, 2025 | Compensation for services other than consulting (speaking, faculty) Korlym · Endocrinology | $2,300 |
| Corcept Therapeutics Oct 22, 2025 | Honoraria Korlym · Endocrinology | $1,820 |
| Corcept Therapeutics Aug 27, 2025 | Compensation for services other than consulting (speaking, faculty) Korlym · Endocrinology | $1,550 |
| Medtronic, Inc. Jan 22, 2025 | Travel and Lodging MINIMED 780G · Durable Pump · travel to Phoenix, AZ · in-kind | $550 |
| Corcept Therapeutics Sep 19, 2025 | Travel and Lodging Korlym · Endocrinology · travel to Nashville, TN · in-kind | $547 |
| Corcept Therapeutics Sep 19, 2025 | Travel and Lodging Korlym · Endocrinology · travel to Nashville, TN · in-kind | $258 |
| Corcept Therapeutics Oct 22, 2025 | Travel and Lodging Korlym · Endocrinology · travel to Nashville, TN | $35.00 |
| Novo Nordisk Inc Aug 11, 2025 | Education Ozempic · Diabetes · in-kind | $32.27 |
| Novo Nordisk Inc Aug 11, 2025 | Education Ozempic · Diabetes · in-kind | $32.27 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 3 industry-funded studies in 2025, from 1 companies. The companies reported $263,891 in research payments for these studies, mostly to the institutions running them.
- A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants
AbbVie Inc. · Active, not recruiting · NCT06345339 - M21-341 - A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants
AbbVie Inc. - A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants
AbbVie Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.